(Q36746441)

16 August 2017

1 reference

title

PET and PET/CT for response evaluation in lymphoma: current practice and developments (English)

1 reference

16 August 2017

3

Gregor Verhoef

0 references

author name string

Lieselot Brepoels

series ordinal

1

1 reference

16 August 2017

Sigrid Stroobants

series ordinal

2

1 reference

16 August 2017

publication date

1 February 2007

1 reference

16 August 2017

1 reference

16 August 2017

volume

48

1 reference

16 August 2017

issue

2

1 reference

16 August 2017

page(s)

270-282

1 reference

Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F10428190601078118

Computed tomography and 18F-FDG positron emission tomography for therapy control of Hodgkin's and non-Hodgkin's lymphoma patients: when do we really need FDG-PET?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601078118

Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin's disease and non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601078118

Evaluation of therapy for lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601078118

Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601078118

Can positron emission tomography with [(18)F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601078118

Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601078118

18FDG-PET following treatment as valid predictor for disease-free survival in Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601078118

FDG PET in the follow-up management of patients with newly diagnosed Hodgkin and non-Hodgkin lymphoma after first-line chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601078118

Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601078118

FDG-PET is superior to gallium scintigraphy in staging and more sensitive in the follow-up of patients with de novo Hodgkin lymphoma: a blinded comparison.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601078118

Positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual Hodgkin's disease mediastinal masses

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601078118

Potential pitfalls of 18F-FDG PET in a large series of patients treated for malignant lymphoma: prevalence and scan interpretation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601078118

Long-term efficacy of the CHVmP/BV regimen used for aggressive non-Hodgkin's lymphoma in three randomised EORTC trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601078118

Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601078118

Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin's lymphoma (NHL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601078118

Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601078118

18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) for staging and follow-up of marginal zone B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601078118

FDG-PET in immunocompetent patients with primary central nervous system lymphoma: correlation with MRI and clinical follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601078118

PET and restaging of malignant lymphoma including residual masses and relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601078118

Positron emission tomography with [18F]FDG for therapy response monitoring in lymphoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601078118

FDG-PET scanning for detection and staging of extranodal marginal zone lymphomas of the MALT type: a report of 42 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601078118

Comparison of prognostic models in patients with advanced Hodgkin disease. Promising results from integration of the best three systems.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601078118

Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601078118

Randomized study to evaluate the use of high-dose therapy as part of primary treatment for "aggressive" lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601078118

Early restaging positron emission tomography with ( 18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601078118

18FDG positron emission tomography versus 67Ga scintigraphy as prognostic test during chemotherapy for non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601078118

Early therapy monitoring with FDG-PET in aggressive non-Hodgkin?s lymphoma and Hodgkin?s lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601078118

[18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601078118

FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601078118

Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601078118

FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601078118

Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601078118

Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601078118

Pre-transplant positron emission tomography (PET) using fluorine-18-fluoro-deoxyglucose (FDG) predicts outcome in patients treated with high-dose chemotherapy and autologous stem cell transplantation for non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601078118

Value of F-18 fluorodeoxyglucose positron emission tomography for predicting the clinical outcome of patients with aggressive lymphoma prior to and after autologous stem-cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601078118

Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601078118

FDG-PET/CT in re-staging of patients with lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601078118

Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging--do we need contrast-enhanced CT?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601078118

Is CT scan still necessary for staging in Hodgkin and non-Hodgkin lymphoma patients in the PET/CT era?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601078118

Accuracy of transmission CT and FDG-PET in the detection of small pulmonary nodules with integrated PET/CT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601078118

Imaging proliferation in vivo with [F-18]FLT and positron emission tomography.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601078118

[18F]FLT-PET in oncology: current status and opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601078118

10.1080/10428190601078118

21 January 2018

Identifiers

DOI

1 reference

16 August 2017

1 reference